Warts Therapeutics and Companies Pipeline Review H1 2015

DALLAS, February 5, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Warts - Pipeline Review, H1 2015" to its store. This report provides an overview of the Warts' therapeutic pipeline and key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

The report "Warts - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Warts , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

Warts are common growths in the skin that are caused by human papillomavirus infection. Warts can spread by contact with the wart or anything that touches it. Warts can grow anyplace on a person's body. There are various kinds of warts that include Common, Flat, Plantar & Filiform warts. Common warts - often appear on your fingers, Plantar warts - show up on the soles of feet. Genital warts are considered as a sexually transmitted disease. Warts are common in children & occur between ages 12 to 16 years.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269580 . (This is a premium report priced at US$2000 for a single user License.)

Companies discussed in this Warts - Pipeline Review, H2 2014 report include 3M Drug Delivery Systems, Agilvax, Inc., Anaconda Pharma, BioMAS Ltd., Burke Pharmaceuticals, LLC, Cutanea Life Sciences, Foamix Pharmaceuticals Ltd., G&E Herbal Biotechnology Co., Ltd., Helix BioPharma Corp., NanoViricides, Inc., Nielsen Biosciences, Inc. and ViroStatics, srl.

Drugs Profiles discuss in this report include 854-A, A-101, AP-611074, AS-101, AX-03, BURKE-201, Candida Albicans Antigen, HerpeCide-I, imiquimod, interferon alpha-2b, PP-210 and SRT-100.

Scope of Warts - Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Warts; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Warts and enlists all their major and minor projects; report summarizes all the dormant and discontinued pipeline projects; A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Warts pipeline on the basis of target, MoA, route of administration and molecule type; Latest news and deals relating related to pipeline products

Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269580 . (This is a premium report priced at US$2000 for a single user License.)

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Warts
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Dermatology therapeutics @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .

Get more reports on Dermatology therapeutics:

Chronic Plaque Psoriasis - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis. Chronic plaque psoriasis, the most common form of psoriasis, is a papulosquamous disease defined by erythematous plaques with a silvery scale. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Companies discuss in the report include AbGenomics International, Inc., Actelion Ltd, Almirall, S.A., ApoPharma Inc., Biotest AG, Boehringer Ingelheim GmbH, Can-Fite BioPharma Ltd., Coherus BioSciences, Inc., Covagen AG, Eli Lilly and Company, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Novartis AG, OPKO Health, Inc., Pfizer Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Takeda Pharmaceutical Company Limited, UCB S.A., XenoPort, Inc.

Mild Psoriasis - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis. Companies discuss in the report include Avexxin AS, Convoy Therapeutics, Inc., Delenex Therapeutics AG, GlycoMar Limited, OPKO Health, Inc., Soligenix, Inc., UCB S.A.

Drugs Profiles discuss in this report AKP-11, AVX-001, cyclosporine, DLX-105, DLX-3003, GLY-2028, lunacalcipol, SGX-301, UCB-5857.

About Us: 

RnRMarketResearch.com is a database of selected syndicated market reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Contact:   

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com